Cote d’Ivoire Pharmaceuticals and Healthcare Report Q3 2013:Life Sciences Market Research Reports

Life Sciences Market Research Reports

Cote d'Ivoire Pharmaceuticals and Healthcare Report Q3 2013 May 15th 2013, 00:00 BMI View: The risks of investing in Côte d’Ivoire’s pharmaceutical and healthcare industry are numerous. Politically, the country is in a fragile state, with concerns over security commonplace. Economically, Côte d’Ivoire posts a better performance, but there are many challenges to doing business in the country, not least the presence of substandard drugs, lack of trained healthcare personnel, weak IP framework and supply chain concerns (such as a lack of suitable storage facilities in rural areas). Domestic drug production – essential to reduce the government’s expensive import bill – is limited; only a few manufacturing facilities exist, mainly for the … Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=96057. Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/cote-divoire-pharmaceuticals-and-healthcare-report-q3-2013-market-report.html.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions